Ataciguat sodium
Modify Date: 2024-01-12 19:03:04
Ataciguat sodium structure
|
Common Name | Ataciguat sodium | ||
|---|---|---|---|---|
| CAS Number | 254976-06-2 | Molecular Weight | 598.46 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C21H18Cl2N3NaO6S3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Ataciguat sodiumAtaciguat (HMR-1766) is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.51 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC; increases cGMP levels in cultured rat aortic smooth muscle cells; induces vasorelaxation of isolated endothelium-denuded rat aorta, porcine coronary arteries, and human corpus cavernosum with EC50 of 1-10 uM; decreases arterial blood pressure in anesthetized pigs. Heart Failure Phase 2 Clinical |
| Name | Ataciguat sodium |
|---|
| Description | Ataciguat (HMR-1766) is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.51 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC; increases cGMP levels in cultured rat aortic smooth muscle cells; induces vasorelaxation of isolated endothelium-denuded rat aorta, porcine coronary arteries, and human corpus cavernosum with EC50 of 1-10 uM; decreases arterial blood pressure in anesthetized pigs. Heart Failure Phase 2 Clinical |
|---|---|
| References | References 1. Schindler U, et al. Mol Pharmacol. 2006 Apr;69(4):1260-8. 2. Evgenov OV, et al. Nat Rev Drug Discov. 2006 Sep;5(9):755-68. 3. Schäfer A, et al. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2813-8. 4. Zhou Z, et al. Am J Physiol Heart Circ Physiol. 2008 Oct;295(4):H1763-71. View Related Products by Target Guanylate Cyclase Heart Failure |
| Molecular Formula | C21H18Cl2N3NaO6S3 |
|---|---|
| Molecular Weight | 598.46 |